Endovascular Thrombectomy

Among patients with ischemic stroke and mismatch imaging profiles, the performance of endovascular thrombectomy correlated with improvements in clinical outcomes, according to a study published in JAMA Neurology.

Lumosa Therapeutics announced its novel agent for patients with acute ischemic stroke met the primary safety endpoint in a phase 2 trial.

Results of a meta-analysis published in Neurology determined there was no difference in functional outcomes between direct thrombectomy and combination with bridging IV thrombolysis among Asian patients with large vessel occlusion stroke.

Delays in care after acute ischemic stroke correlated with loss of healthy life-years among patients treated with endovascular thrombectomy, especially in the post-arrival period, according to findings published in JAMA Neurology.

An interim analysis of the SWEDEPAD trial, which was paused after a meta-analysis detected a mortality hazard associated with paclitaxel-coated devices, found no death risk from the devices in patients with peripheral artery disease.

Among patients with acute ischemic stroke from large-vessel occlusion, endovascular thrombectomy alone was noninferior for 90-day functional outcomes to IV alteplase administered within 4.5 hours from symptom onset plus endovascular thrombectomy.

Dosage comparison of tenecteplase (TNKase, Genentech) in patients with acute ischemic stroke who had thrombectomy.

Nerinetide (NA-1, NoNO Inc.) for neuroprotection in patients having endovascular therapy for acute ischemic stroke.